HbA1c Targets for Diabetes Management

General Recommendations

The American Diabetes Association recommends a target HbA1c of <7% (53 mmol/mol) for many nonpregnant adults with diabetes, supported by strong evidence from major clinical trials 1, 2
Each 10% reduction in HbA1c is associated with a 44% lower risk for progression of diabetic retinopathy 1
A target HbA1c of <7% (53 mmol/mol) is appropriate for many nonpregnant adults with diabetes, and applies only when using assay methods certified as traceable to the DCCT reference 1, 2

The American College of Physicians recommends a target range of 7-8% for most nonpregnant adults with type 2 diabetes, with consideration of individual patient characteristics and risk of hypoglycemia 3, 2
Patients with a history of severe hypoglycemia, limited life expectancy, or advanced microvascular or macrovascular complications may require less stringent targets (7.5-8.5%) 2, 1, 6
Patients on medications associated with hypoglycemia should aim for a target HbA1c of 7% 4

Intensive glycemic control (HbA1c <7%) significantly increases risk of hypoglycemia, especially in those with advanced kidney disease (CKD stages 4-5) 6
The American Journal of Kidney Diseases recommends not treating to an HbA1c target of <7.0% in patients with CKD who are at risk of hypoglycemia 6
Hypoglycemia risk is a critical factor in determining appropriate targets, as it can lead to falls, cognitive impairment, and potentially increased mortality 5, 6

Assess individual patient characteristics, including age, duration of diabetes, comorbidities, and hypoglycemia risk, to determine appropriate HbA1c targets 1, 5
Monitor HbA1c at least twice yearly in patients meeting treatment goals with stable glycemic control, and quarterly in those with therapy changes or not meeting goals 7
Serial quarterly measurements have been associated with significant reductions in HbA1c values 7

Setting overly aggressive targets (HbA1c <6.5%) for patients with multiple comorbidities or at high risk for hypoglycemia 6, 5
Failing to adjust targets as patient circumstances change (e.g., development of comorbidities, aging) 5
Overlooking the increased risk of hypoglycemia with intensive control, especially in patients with renal impairment 6